Sugi Predict

Sugi Predict / Compounds / SCHEMBL4388005

SCHEMBL4388005

SCHEMBL4388005

CC1(C)C(=O)NCCN1C(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 1/20 0.46
▸ NPC1 O15118 4/20 0.45
▸ RAB9A P51151 4/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ GAA P10253 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ GLA P06280 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ DDB1 Q16531 1/20 0.42
▸ CRBN Q96SW2 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23388916 0.88 HTR2C (0.44) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL27526701 0.86 SMN1; SMN2 (0.44) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL27527043 0.85 SMN1; SMN2 (0.43) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL12816594 0.81 OPRK1 (0.45) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL1445254 0.81 OPRK1 (0.45) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL1226725 0.79 SMN1; SMN2 (0.44) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL1227266 0.79 SMN1; SMN2 (0.44) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL1226722 0.79 SMN1; SMN2 (0.44) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL27551346 0.79 SMN1; SMN2 (0.43) HTR2CNPC1RAB9ASMN1; SMN2GAA
SCHEMBL15000800 0.78 HTR2C (0.50) HTR2CNPC1RAB9ASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
US-20240252655-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS NOVARTIS AG (CH) 2024-08-01 — — US disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
EP-4329815-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS Novartis AG (CH) 2024-03-06 — — EP disclosed
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-01 — — US disclosed
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 — — US disclosed
EP-1051176-B1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMA INC (US) 2006-11-22 — — EP disclosed
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 — — US disclosed
EP-1051176-A4 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARM PROD INC (US) 2002-06-12 — — EP disclosed
EP-1208097-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS Aventis Pharmaceuticals Inc. (US) 2002-05-29 — — EP disclosed
CN-1291892-A Substituted oxoazaheterocyclyl factor Xa inhibitors AWENTIS PHARMACEUTICAL INC (US) 2001-04-18 — — CN disclosed
WO-2001007436-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS AVENTIS PHARMACEUTICALS INC. (US) 2001-02-01 — — WO disclosed
EP-1051176-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2000-11-15 — — EP disclosed
WO-2000032590-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-06-08 — — WO disclosed
WO-1999037304-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240252655-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS USP2, USP1, USP28 HTR2C 4150/4885NPC1 2103/4885RAB9A 996/4885
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds F13B, F9, F11 HTR2C 1330/4885NPC1 2223/4885RAB9A 1986/4885
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB HTR2C 4610/4885NPC1 3576/4885RAB9A 2104/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB HTR2C 4610/4885NPC1 3576/4885RAB9A 2104/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB HTR2C 4610/4885NPC1 3576/4885RAB9A 2104/4885
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GBA2, CLN6 HTR2C 853/4885NPC1 20/4885RAB9A 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.